ScreenerHero

CLCresco Labs Inc.

CNQ · CA · Healthcare · Drug Manufacturers - Specialty & Generic · crescolabs.com
1.030CAD-4.63%Mkt Cap: 278.93M $P/E: —

Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$62.66BUSDP/E 24.3
TAK
Takeda Pharmaceutical Company Limited
$60.33BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.72BUSDP/E 66.8
HLN
Haleon plc
$41.16BUSDP/E 19.5
ZTS
Zoetis Inc.
$29.48BUSDP/E 11.6
ZOE
Zoetis Inc.
$27.77BUSDP/E 11.6
UTHR
United Therapeutics Corporation
$21.22BUSDP/E 17.7
VTRS
Viatris, Inc.
$19.47BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.80BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.63BUSDP/E 21.0
IPN
Ipsen S.A.
$13.27BUSDP/E 24.0
ELAN
Elanco Animal Health Incorporated
$11.20BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.33BUSDP/E 30.2
KRK
Krka, d. d.
$8.66BUSDP/E 18.8
ALKS
Alkermes plc
$7.41BUSDP/E 116.3
AMRX
Amneal Pharmaceuticals, Inc.
$7.02BUSDP/E 42.0
HIMS
Hims & Hers Health, Inc.
$6.85BUSD
LNTH
Lantheus Holdings, Inc.
$6.55BUSDP/E 24.0
KNSA
Kiniksa Pharmaceuticals International, plc
$6.10BUSDP/E 78.9
LQDA
Liquidia Corporation
$5.95BUSDP/E 47.5

Key Statistics

Company
Market Cap278.93M $
Enterprise Value622.49M $
Revenue (TTM)474.19M $
Gross Profit236.37M $
Net Income (TTM)-98.61M $
Revenue/Share1.307 USD
Last Price1.030 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.9K
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-18.76
PEG—
EV/EBITDA7.69
EV/Revenue1.31
P/S0.60
P/B0.79
EPS (TTM)-0.39
EPS (Forward)-0.06
52W Range
0.89006% of range3.120
52W High3.120 CAD
52W Low0.8900 CAD
Profitability
Gross Margin49.49%
Oper. Margin7.71%
EBITDA Margin17.07%
Profit Margin-20.65%
ROE-39.77%
ROA-11.31%
Growth
Revenue Growth5.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF53.08M $
CapEx (TTM)27.81M $
FCF Margin3.83%
FCF Yield6.51%
Net Debt407.20M $
Net Debt/EBITDA5.03
Balance Sheet
Debt/Equity1.72
Current Ratio1.78
Quick Ratio0.53
Book Value/Sh1.336 CAD
Cash/Share0.0880 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:812.63
Split DateDec 3, 2018
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2.543 CAD
Upside (mean)+146.9%
Target Range2.338 CAD – 2.745 CAD
CAD2.338+146.9% to meanCAD2.745
# Analysts4
Ownership
Shares Out.355.59M
Float346.32M
Insiders2.05%
Institutions3.45%
Short Interest
Short Ratio0.3d
Short % Float0.01%
Short % Out.0.00%
Shares Short17.48K
Short (prev mo.)9.42K
Technical
SMA 501.032 (-0.2%)
SMA 2001.303 (-21.0%)
Beta1.77
S&P 52W Chg14.29%
Avg Vol (30d)76.64K
Avg Vol (10d)53.97K
Technical Indicators
RSI (14)52.6
MACD0.0065
MACD Signal-0.0096
MACD Hist.+0.0161
BB Upper1.158 CAD
BB Middle1.010 CAD
BB Lower0.8635 CAD
BB Width29.10%
ATR (14)0.0652 CAD
Vol Ratio (20d)0.77x